ARIC Manuscript Proposal # 1549

1.a. Full Title: ICBP GWAS for BP (SBP, DBP, HTN) top findings: rare variant analysis in ARIC

b. Abbreviated Title (Length 26 characters): BP_firstVisit rare variant (ICBP)

2. Writing Group: FEHGAS working group
   ARIC writing group members: Georg Ehret, Aravinda Chakravarti. If the results will be used jointly with other data from CHARGE or ICBP: Other authors from these cohorts. The plan is to maintain symmetry across cohorts.

   The following co-authors are also invited to join this proposal (could not be reached because of the summer holidays): Eric Boerwinkle, Josef Coresh, Santhi Ganesh, Xiaofeng Zhu

   I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal: YES

First author: Georg B. Ehret
Address: Johns Hopkins University School of Medicine
         733 N. Broadway, BRB 453
e-mail: georg@jhmi.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Eric Boerwinkle
Address: University of Texas Health Science Center at Houston School of Public Health
1200 Herman Pressler Dr.
Houston, Texas 77030
United States
Phone: (713) 500-9800
Eric.Boerwinkle@uth.tmc.edu

3. Timeline: spring 2010

4. Rationale: Persistent elevated blood pressure (BP), diagnosed as hypertension (HTN), is quantitatively the major cardiovascular risk factor with a population prevalence of ~30%. Pathogenic pathways that lead to HTN remain poorly understood. A distinct fraction of the hypertension risk is genetic and this opens the possibility for genetic investigations to contribute to a better understanding of this trait and possible identification of new molecular targets for drug therapy.

   ARIC has recently published a first genome-wide association study (GWAS) on SBP and DBP within the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. The corresponding manuscript proposal was
named “CHARGE GWAS for BP (SBP and DBP) at first visit”. The total sample size of this consortium including AGES, CHS, FHS, and ERGO is ~25,000.

Several genome-wide significant variants in hypertension genes were identified and replicated in a similar study by a consortium of mainly European cohorts (named “global BP GEN” (GBPGEN)). The total sample size of GBPGEN is similar to CHARGE.

We have subsequently proposed a joint analysis of CHARGE and GBPGEN (manuscript proposal: BP_firstVisit GWAS (ICBP)). The total sample size of the combined cohorts is ~80,000. This project is currently in the replication phase and a manuscript is being written.

We propose here to use the most significant findings from ICBP to conduct a rare variant analysis by halplotyping in ARIC. We will analyze all three phenotypes treated in ICBP: SBP, DBP, and HTN at the first visit.

5. Main Hypothesis/Study Questions:
Additional rare gene variants can be identified using a haplotype analysis.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).
Design: We will use MACH (Abecasis lab) and similar tools to calculate haplotypes in a fixed region around the most significant hits of the ICBP analysis. Phenotypic and genotypic outliers of the ARIC study will be excluded.

Phenotypes: SBP, DBP, and HTN at first visit

a) Model: Linear regression for cross-sectional analysis
The main analysis will include only self-reported whites (no self-reported African Americans included)

Genetic model: additive.

b) Transform: no transformation, no scaling.

c) Covariates: age, age^2, sex, bmi, study-center

d) Exclusions: outliers of the SBP/DBP distribution (>/< +/- 4SD)

e) Control for multiple comparisons: Bonferroni or similar adjustment adjustment

f) Imputation
None

g) Meta-analysis:
Not yet planned, but might be conducted.

7.a. Will the data be used for non-CVD analysis in this manuscript?
No
b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used?

NA

(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript?

Yes

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?

Yes

8.c. If yes, is the author aware that the participants with RES_DNA = ‘not for profit’ restriction must be excluded if the data are used by a for profit group?

Yes

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.cscc.unc.edu/ARIC/search.php

Yes (based on list circulated in July 2008).

This proposal has some overlap, but is distinct from a proposal submitted by Xiaofeng Zhu. He and his group is conducting a genome-wide rare variant analysis which has different opportunities and different power from this focused approach.

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

Cf. above.

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?

Yes

11.b. If yes, is the proposal
   ___ A. primarily the result of an ancillary study (list number* __________)
   ___ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* 2006.03

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.